A new GLP-1 drug, pemvidutide, helped patients lose fat while guarding muscle, like exercise does.
That's impressive when you compare it to existing GLP-1 drugs like Ozempic and Wegovy (semaglutide), or Mounjaro and Zepbound (tirzepatide).
This is why doctors recommend patients on weight loss drugs do some strength training in tandem with their medication.
Pemvidutide, like tirzepatide is a two-part drug that combines a GLP-1 drug with another drug in a single shot.
"There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss," Scott Harris, Altimmune's chief medical officer, said in a release.
Persons:
Drugmakers Eli Lilly, —, Drugmaker Altimmune, Altimmune, Scott Harris, Eli Lilly, FierceBiotech, Versanis
Organizations:
Novo Nordisk, Service
Locations:
Altimmune, GLP